Parabilis Medicines set a large biotech listing milestone, completing a $770.5 million IPO via the Nasdaq after underwriters exercised their overallotment option. The listing follows a streak of record-sized U.S. biotech IPOs, including Kailera Therapeutics’ prior benchmark, and signals sustained investor appetite despite a mixed macro backdrop. The report frames the resurgence as the release of earlier “pent-up” life-sciences capital that shifted into venture funding during slower public-market periods. It also notes that both the IPO and acquisition windows have helped unlock liquidity. For biotech leaders, these listings can accelerate pipeline funding and broaden the set of potential strategic partners as companies seek scale-ready capital.